In an effort to help boost the global battle against tuberculosis (TB), the National Institute of Allergy and Infectious Diseases (NIAID) has developed a research agenda intended to complement domestic and international efforts to control the disease. The NIAID agenda is focused on biomedical research centered on drug-resistant TB and extensively drug-resistant TB.
The agenda will harmonize with current research that is already in place, such as the efforts being made by the CDC and the World Health Organization’s STOP TB partnership.
Areas of biomedical research that are probable contributors to a global public health response to TB are identified in the agenda.
“The challenge of TB control is further compounded by the rise of drug-resistant TB, and we anticipate that the NIAID research agenda for multi drug resistant and extensively drug resistant tuberculosis will contribute substantively to the fight against this emerging threat,” says Anthony S. Fauci, MD, author of the agenda.
A summary of the NIAID’s agenda is available online in the Journal of Infectious Diseases.
